University of Kentucky researchers have discovered a surprising culprit behind the sleep loss that plagues Alzheimer's patients — and found a way to reverse it.

In a study published in the journal Alzheimer's & Dementia, a team led by Dr. Shannon L. Macauley and first author Dr. Nicholas J. Constantino revealed that overactive microglia — the brain's resident immune cells — are the primary drivers of sleep disruption in Alzheimer's disease.

This overturns previous assumptions. Scientists had long believed that sleep loss in Alzheimer's was caused by the accumulation of amyloid plaques or the death of neurons. Instead, the research shows that microglia, when they respond to plaques, trigger a cascade of inflammation that effectively keeps the brain awake.

"Basically, we showed that it is not the plaques themselves, or solely dysfunctional neurons, that cause sleep loss but actually microglia," Macauley said. "Microglia are immune cells that, when they respond to plaques, kick off this elaborate cascade of inflammation, as if the microglia are partying all night and keeping the brain awake."

The team used a drug to temporarily remove microglia in Alzheimer's-model mice. After a 14-day treatment that eliminated 87% of microglia, the mice regained more than two hours of sleep per day — without altering the underlying amyloid plaque burden at all. This demonstrates that the sleep disruption is a reversible immune-driven process, not a fixed consequence of plaque accumulation.

Macauley described the finding as "paradigm shifting" because it opens an entirely new therapeutic target for treating Alzheimer's symptoms. Instead of focusing solely on clearing plaques or protecting neurons, drugs could be developed to modulate the inflammatory response of microglia, potentially improving sleep quality for millions of Alzheimer's patients.

Sleep loss affects up to 60% of people with Alzheimer's and is often one of the most distressing symptoms for both patients and caregivers. Poor sleep is also believed to accelerate cognitive decline, creating a vicious cycle. The discovery that this symptom can be reversed independently of plaque removal offers hope for interventions that could improve quality of life at any stage of the disease.

The researchers are now investigating whether similar mechanisms could be at play in other neurodegenerative conditions associated with sleep disruption, and whether longer-term microglial modulation could have additional cognitive benefits beyond sleep restoration.

Sources